(Q44846098)

6 December 2017

title

Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate (English)

1 reference

6 December 2017

2

Eitaro Aihara

1 reference

6 December 2017

Kenji Kanatsu

1

1 reference

6 December 2017

Mituaki Okayama

series ordinal

3

1 reference

6 December 2017

Shinichi Kato

series ordinal

4

1 reference

6 December 2017

Koji Takeuchi

series ordinal

5

1 reference

6 December 2017

publication date

1 May 2004

1 reference

Journal of Gastroenterology and Hepatology

6 December 2017

published in

1 reference

6 December 2017

volume

19

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

512-520

1 reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

Nonclinical model for assessing gastric effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

Alendronate gastric ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

Alendronate induces gastric injury and delays ulcer healing in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

Endogenous nitric oxide in gastric alkaline response in the rat stomach after damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

Esophageal irritation due to alendronate sodium tablets: possible mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03314.X

10.1111/J.1440-1746.2003.03314.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference